Lyell Immunopharma, Inc.
LYEL· Nasdaq
LYELLyell Immunopharma, Inc.
Filed Aug 4, 2022 · 10-Q · 35 days after period end · 0001628280-22-021109
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Revenue | $35.74M | $2.63M | $3.12M |
| Net Income | -$36.32M | -$62.60M | -$100.66M |
| EPS Diluted | -$0.15 | -$1.47 | -$8.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end
